Search clinical trials for: anti-CD19/22-CAR vector-transduced T cells

Total 471 results

Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | Prolymphocytic Leukemia and other conditions

China
Chinese PLA General Hospital

Unknown

CART-19 Immunotherapy in Mantle Cell Lymphoma

Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Non-hodgkin Lymphoma,B Cell

China
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 (CART19)

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Chinese PLA General Hospital

Completed

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

Non-hodgkin's Lymphoma

China
Chinese PLA General Hospital

Unknown

A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia

B Cell Leukemia

China
University of Colorado, Denver

Recruiting

UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1

Acute Lymphoblastic Leukemia | Acute Lymphoid Leukemia

United States
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/22 Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
Dr. Melody Smith, MD, MS
Orca Biosystems, Inc.

Recruiting

Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric Antigen Receptor) T Cells in Adults With B-cell Acute Lymphoblastic Leukemia (ALL)

Lymphoid Leukemia

United States
Chinese PLA General Hospital

Completed

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133

Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Brain Tumor | Liver Cancer | Ovarian Tumor | Acute Myeloid and Lymphoid Leukemias

China
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso

Pancreatic Cancer | Malignant Mesothelioma | Triple Negative Breast Cancer | Endometrial Cancer | Ovarian Tumor | Other Mesothelin Positive Tumors

China
Chinese PLA General Hospital

Unknown

Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
National Cancer Institute (NCI)

Completed

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

Lymphoma, B-Cell | Leukemia, B-cell | Lymphoma, Hodgkins | Lymphoma, Non-hodgkins

United States
Southwest Hospital, China

Unknown

the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)

Lymphoma, Large B-Cell, Diffuse

China
Miltenyi Biomedicine GmbH

Recruiting

MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)

B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent | Acute Lymphoblastic Leukemia Recurrent | Chronic Lymphocytic Leukemia Recurrent | Chronic Lymphocytic Leukemia Refractory

Germany
Southwest Hospital, China

Unknown

A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies

Myeloid Malignancies

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First People's Hospital of Hefei; Hefei Binhu Hospital

Unknown

CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor

Malignant Glioma of Brain | Gastric Carcinoma | Colorectal Carcinoma

China
Affiliated Hospital to Academy of Military Medical...

Unknown

Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies

Lymphoma | Leukemia

China
Miltenyi Biomedicine GmbH

Not yet recruiting

MB-CART19.1 in Refractory SLE

SLE - Systemic Lupus Erythematosus

Germany
Southwest Hospital, China

Unknown

A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies

Lymphoma | Leukemia

China
Southwest Hospital, China

Unknown

A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies

Lymphoma | Leukemia

China
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma

Non-hodgkin Lymphoma,B Cell

China
Southwest Hospital, China

Unknown

A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies

Leukemia

China
Southwest Hospital, China

Unknown

A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies

Lymphoma | Leukemia | Multiple Myeloma

China
Southwest Hospital, China

Unknown

A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies

Lymphoma | Leukemia

China
Southwest Hospital, China

Unknown

A Clinical Research of LeY-Targeted CAR-T in Myeloid Malignancies

Myeloid Malignancies

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First People's Hospital of Hefei; Hefei Binhu Hospital

Unknown

Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor

Hepatocellular Carcinoma | Non-small Cell Lung Cancer | Pancreatic Carcinoma | Triple-Negative Invasive Breast Carcinoma

China
Shenzhen Institute for Innovation and Translational...
Dongguan People's Hospital

Completed

Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies

Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia

China
Second Affiliated Hospital of Guangzhou Medical...
Guangzhou First People's Hospital; First People's Hospital of Foshan; Dongguan... and other collaborators

Unknown

A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies

Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia

China
Autolus Limited

Completed

CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) (AMELIA)

Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | B-cell Acute Lymphoblastic Leukemia | Refractory Childhood Acute Lymphoblastic Leukemia

United Kingdom
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma,B Cell

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis

Vasculitis | Amyloidosis | Autoimmune Hemolytic Anemia | POEMS Syndrome

China
KK Women's and Children's Hospital
Singapore General Hospital

Recruiting

CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol

Lymphoblastic Leukemia | Lymphoblastic Leukemia, Acute Adult | Lymphoblastic Leukemia in Children | CAR | B-cell Acute Lymphoblastic Leukemia | Large B-cell Lymphoma

Singapore
The Children's Hospital of Zhejiang University...
Chongqing Precision Biotech Co., Ltd

Recruiting

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Systemic Lupus Erythematosus

Systemic Lupus Erythematosus | CAR-T Cell Therapy

China
Xinqiao Hospital of Chongqing
Xuzhou Medical University

Unknown

Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients (MendCART)

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Follicular Lymphoma | Stage III/IV Adult Diffuse Large Cell Lymphoma | Stage III/IV Follicular Lymphoma | Stage III/IV Mantle Cell Lymphoma

China
University College, London
Deutsche Krebshilfe e.V., Bonn (Germany); European Union; The Leukemia and Lymphoma... and other collaborators

Terminated

CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL) (CD19TPALL)

Acute Lymphoblastic Leukemia

United Kingdom, Germany
Peking Union Medical College Hospital
Cellular Biomedicine Group Ltd.

Completed

A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects

B-cell Non-Hodgkin Lymphoma

China
Seattle Children's Hospital

Active, not recruiting

Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia

CD 19+ Acute Leukemia

United States
Yan'an Affiliated Hospital of Kunming Medical University
KAEDI

Unknown

CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia

B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

China
Zhejiang University
Shanghai YaKe Biotechnology Ltd.

Recruiting

CD19-BAFF CAR-T Cells Therapy for Patients With Autoimmune Diseases

Autoimmune Diseases

China
University College, London

Enrolling by invitation

A New Study Evaluating the Activity of Modular CAR T for mYeloma (MCARTY)

Multiple Myeloma

United Kingdom
Liqun Zou

Recruiting

Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies

Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Leukemia

China
Yan'an Affiliated Hospital of Kunming Medical University

Recruiting

Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia

B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

China
Zhejiang University
Shanghai YaKe Biotechnology Ltd.

Not yet recruiting

CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL

Non-hodgkin Lymphoma,B Cell | Acute Lymphoblastic Leukemia,B-Cell

China
Beijing GoBroad Hospital

Recruiting

Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients

Acute Lymphoblastic Leukemia, in Relapse | B-cell Acute Lymphoblastic Leukemia | Refractory Acute Lymphoid Leukemia

China
University of Pennsylvania

Terminated

CD19 Redirected Autologous T Cells for Hodgkin Lymphoma

Hodgkin Lymphoma With no Available Curative Treatment Options Who Have a Limited Prognosis

United States
Shanghai Unicar-Therapy Bio-medicine Technology...
The First Affiliated Hospital of Soochow University

Recruiting

Humanized CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Relapse | CD19 Positive | Refractory

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies

CAR

China
Shanghai Unicar-Therapy Bio-medicine Technology...
The First Affiliated Hospital of Soochow University

Recruiting

CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia

B-cell Acute Lymphocytic Leukemia

China

Search clinical trials for: anti-CD19/22-CAR vector-transduced T cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations